Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Taysha Gene Therapies Inc shares valued at $2,062,500 were purchased by Manning Paul B on May 30 ’25. At $2.75 per share, Manning Paul B acquired 750,000 shares. The insider’s holdings grew to 2,841,704 shares worth approximately $7.59 million following the completion of this transaction.
Also, Manning Paul B purchased 1,333,333 shares, netting a total of over 2,999,999 in proceeds. Following the buying of shares at $2.25 each, the insider now holds 1,333,333 shares.
As published in their initiating research note from BMO Capital Markets on June 27, 2024, Taysha Gene Therapies Inc [TSHA] has been an Outperform and the price target has been revised to $5. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in early April. As of February 01, 2023, Jefferies has decreased its “Buy” rating to a “Hold” for TSHA. Earlier on January 27, 2023, Morgan Stanley downgraded its rating. Their new recommendation was “an Equal-weight” for TSHA stock which previously was a “an Overweight”.
Analyzing TSHA Stock Performance
During the last five days, there has been a drop of approximately -4.30%. Over the course of the year, Taysha Gene Therapies Inc shares have jumped approximately 54.34%. Shares of the company reached a 52-week high of $3.24 on 05/21/25 and a 52-week low of $1.05 on 04/09/25.
Support And Resistance Levels for Taysha Gene Therapies Inc (TSHA)
According to the 24-hour chart, there is a support level at 2.50, which, if violated, would cause prices to drop to 2.34. In the upper region, resistance lies at 2.92. The next price resistance is at 3.18. RSI (Relative Strength Index) is 54.80 on the 14-day chart, showing neutral technical sentiment.
